Skip Navigation

Your Environment. Your Health.

Etanercept in Adult Dermatomyositis

Principal Investigator:

A. Amato & Muscle Study Group (9 sites)


Study Design:

Randomized, double-blind, placebo-controlled trial of Etanercept (all patients will initially be started on prednisone)


Types & Number of IIM Studied:

Active, new adult dermatomyositis (N = 30)


Entry Criteria:

Definite Dermatomyositis


IMACS Core Set Measures Included:

Physician and Patient Global Activity Assessments, Manual Muscle Testing, Health Assessment Questionnaire


Other Measures Included:

Cutaneous Assessment Disease Activity Severity Index (CDASI), pulmonary function testing, electrocardiogram, MVICT, magnetic resonance imaging, skin biopsy; DNA microarrays on muscle, skin, and peripheral white blood cells


Primary Outcome:

Cumulative dose of prednisone; Number of treatment failures; Responsiveness of IMACS outcome variables


Study Duration:

12 months



Enrollment Completed



Anthony A. Amato, M.D.
Professor of Neurology
Brigham and Women's Hospital
Neurology, ASB 1-2
75 Francis St
Boston, MA 02115
Tel (617) 732-5436
Fax (617) 730-2885


Return to Therapeutic Studies listing

Back to Top